Immunexpress is a privately owned company creating revolutionary molecular diagnostics for sepsis. The company has offices in Seattle, USA and Brisbane, Australia. Immunexpress's product pipeline aims to address the overwhelming unmet clinical needs of sepsis patients, as well as clinicians, payers and healthcare systems.
Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.
Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $46M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | iQFunds | inqbator.c... |
| - | Debiopharm | debiopharm... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.04.2015 | - | $40M | - |
| 06.03.2014 | - | $6M | - |
Mentions in press and media 9
| Date | Title | Description |
| 21.10.2022 | When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems | Rolland Carlson, CEO of Immunexpress US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating... |
| 30.11.2021 | Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA | PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext B... |
| 16.09.2021 | Immunexpress To Present SeptiCyte RAPID Comparative Data Against Lactate And Procalcitonin For Diagnosing Sepsis At IDWeek 2021 | Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced a presentation demonstrating comparative data of SeptiCyte RAPID, lactate, and procalcitonin in differentiating sepsis... |
| 23.08.2021 | Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis | |
| 03.06.2021 | Gut therapy: MicrobiomX raises $1M for stool collection and processing device, analysis service | MicrobiomX’s device for stool collection also extrudes stool into capsules. (MicrobiomX Photo) New funding: MicrobiomX, a Seattle startup developing a device to collect and process stool samples for clinical use, has raised $1 million in a ... |
| 03.10.2019 | Immunexpress Closes Major Private Funding Round | Immunexpress, Inc., a Seattle, WA-based medical diagnostic company focused on improving outcomes for suspected sepsis patients, closed a major private funding round. The amount of the deal and the backers were not disclosed. The company int... |
| 03.04.2015 | Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour | There’s a reason sepsis still carries such a high mortality rate: For every hour that passes before proper treatment’s administered, a patient’s risk for death rises 7.6 percent. It’s a wildly expensive disease – cost more than $20 billion ... |
| 06.03.2014 | Immunexpress Raises $6M in Funding | Immunexpress Group, a Brisbane, Australia and Seattle, USA-based molecular diagnostic company, raised $6m in funding. The round was led by Debiopharm Diagnostics SA, which is part of the Swiss-based global biopharmaceutical group of compani... |
| - | Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour | Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so, CEO Roz Brandon says. Its approach is to measure a patient’s septic immune respon... |